Compare GABC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GABC | NVAX |
|---|---|---|
| Founded | 1910 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 1995 | 1996 |
| Metric | GABC | NVAX |
|---|---|---|
| Price | $49.50 | $8.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $56.40 | $14.11 |
| AVG Volume (30 Days) | 114.5K | ★ 5.8M |
| Earning Date | 10-26-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | 8.13 | ★ 309.76 |
| EPS | ★ 2.93 | N/A |
| Revenue | $487,401,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $11.03 | N/A |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | $17.00 | ★ N/A |
| Revenue Growth | 37.80 | ★ 64.69 |
| 52 Week Low | $37.73 | $6.20 |
| 52 Week High | $52.39 | $13.39 |
| Indicator | GABC | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 35.18 |
| Support Level | $47.98 | $7.48 |
| Resistance Level | $49.68 | $10.64 |
| Average True Range (ATR) | 1.02 | 0.70 |
| MACD | -0.07 | -0.22 |
| Stochastic Oscillator | 28.38 | 0.16 |
German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.